Arrowhead Pharmaceuticals, Inc. (ARWR) Reaches $64.83 After 8.00% Down Move; Sprague Resources LP (SRLP) Sentiment Is 0.91

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Logo

Sprague Resources LP (SRLP) investors sentiment increased to 0.91 in 2019 Q2. It’s up 0.12, from 0.79 in 2019Q1. The ratio increased, as 11 active investment managers started new or increased holdings, while 14 sold and reduced holdings in Sprague Resources LP. The active investment managers in our database reported: 3.54 million shares, down from 3.80 million shares in 2019Q1. Also, the number of active investment managers holding Sprague Resources LP in top ten holdings was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 8 Increased: 5 New Position: 6.

The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a huge mover today! The stock decreased 5.58% or $3.83 during the last trading session, reaching $64.83. About 5.58M shares traded or 206.32% up from the average. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has risen 107.57% since December 4, 2018 and is uptrending. It has outperformed by 107.57% the S&P500. Some Historical ARWR News: 23/05/2018 – ARROWHEAD PROPERTIES LTD AWAJ.J – HY TOTAL DIVIDEND 40.43 CENTS; 21/05/2018 – Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis; 05/03/2018 USGS: M 1.8 – 5km NE of Lake Arrowhead, CA; 29/03/2018 – Arrowhead Pharma Presenting at Conference Apr 12; 15/05/2018 – Adage Capital Partners GP Buys 1.7% of Arrowhead Pharma; 04/04/2018 – Interior-Parks: Special Tour of Arrowhead Pueblo Offered by Park; 11/04/2018 – Arrowhead Pharma Presenting at Conference Tomorrow; 11/05/2018 – Arrowhead Pharmaceuticals Presents Preclinical Data on Expanding Cardiometabolic Pipeline; 21/04/2018 – DJ Arrowhead Pharmaceuticals Inc, Inst Holders, 1Q 2018 (ARWR); 27/03/2018 – Arrowhead Pharmaceuticals ARO-HBV Is the Second Clinical Candidate Developed Using Arrowhead’s Proprietary Targeted RNAi Molecule TechnologyThe move comes after 7 months negative chart setup for the $6.21B company. It was reported on Dec, 4 by Barchart.com. We have $59.64 PT which if reached, will make NASDAQ:ARWR worth $496.40 million less.

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. The company has market cap of $6.21 billion. The Company’s pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. It has a 93.96 P/E ratio. The firm also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma.

More notable recent Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news were published by: Seekingalpha.com which released: “Arrowhead down 8% premarket on pricing equity offering – Seeking Alpha” on December 04, 2019, also Nasdaq.com with their article: “Health Care Sector Update for 12/04/2019: KOD,HQY,ARWR – Nasdaq” published on December 04, 2019, Nasdaq.com published: “Arrowhead Pharmaceuticals Reaches Analyst Target Price – Nasdaq” on December 04, 2019. More interesting news about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) were released by: Nasdaq.com and their article: “Health Care Sector Update for 12/04/2019: HQY, LCI, ARWR, JNJ, PFE, ABT, MRK, AMGN – Nasdaq” published on December 04, 2019 as well as Fool.com‘s news article titled: “Here’s Why Arrowhead Pharmaceuticals Is Soaring (Again) Today – Motley Fool” with publication date: November 26, 2019.

Among 6 analysts covering Arrowhead Pharmaceuticals (NASDAQ:ARWR), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Arrowhead Pharmaceuticals has $7000 highest and $3900 lowest target. $54’s average target is -16.71% below currents $64.83 stock price. Arrowhead Pharmaceuticals had 10 analyst reports since June 28, 2019 according to SRatingsIntel. The firm has “Buy” rating by Piper Jaffray given on Sunday, October 20. FBR Capital maintained the stock with “Buy” rating in Wednesday, November 13 report. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) earned “Buy” rating by B. Riley & Co on Monday, August 19. The rating was upgraded by Robert W. Baird on Monday, November 25 to “Outperform”. The rating was maintained by Chardan Capital Markets on Tuesday, October 22 with “Buy”. The rating was downgraded by Robert W. Baird to “Neutral” on Thursday, October 24. The rating was maintained by FBR Capital on Monday, October 21 with “Buy”. Cantor Fitzgerald maintained the shares of ARWR in report on Tuesday, November 19 with “Neutral” rating.

Analysts await Sprague Resources LP (NYSE:SRLP) to report earnings on March, 12. They expect $0.83 earnings per share, down 45.03% or $0.68 from last year’s $1.51 per share. SRLP’s profit will be $18.88M for 4.84 P/E if the $0.83 EPS becomes a reality. After $-0.43 actual earnings per share reported by Sprague Resources LP for the previous quarter, Wall Street now forecasts -293.02% EPS growth.

More notable recent Sprague Resources LP (NYSE:SRLP) news were published by: Globenewswire.com which released: “Sprague Resources LP Reports Third Quarter 2019 Results – GlobeNewswire” on November 07, 2019, also Fool.com with their article: “Sprague Resources LP (SRLP) Q3 2019 Earnings Call Transcript – Motley Fool” published on November 07, 2019, Finance.Yahoo.com published: “Mistras Group, Inc. (MG): Hedge Funds Cautiously Bullish – Yahoo Finance” on November 06, 2019. More interesting news about Sprague Resources LP (NYSE:SRLP) were released by: Seekingalpha.com and their article: “Mariner Makes Midstream Mixed – Seeking Alpha” published on November 17, 2019 as well as Globenewswire.com‘s news article titled: “Sprague Resources LP Reports Second Quarter 2019 Results – GlobeNewswire” with publication date: August 07, 2019.

Sprague Resources LP engages in the purchase, storage, distribution, and sale of refined petroleum products and natural gas in the United States. The company has market cap of $365.34 million. The firm operates through four divisions: Refined Products, Natural Gas, Materials Handling, and Other Operations. It has a 7.37 P/E ratio. The Refined Products segment purchases and sells various refined products, such as heating oil, diesel fuel, residual fuel oil, kerosene, jet fuel, gasoline, and asphalt to wholesale and commercial customers.

Sprague Resources LP (NYSE:SRLP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.